Analyst & Firm	Company	Rating & Price Target	Upside / Downside
Marie ThibaultBTIG	ABT Abbott Laboratories	BUY$140	19.07% Upside
William KatzTD Cowen	AB AllianceBernstein	BUY$41	2.83% Upside
Keith HorowitzCiti	ALLY Ally Financial	BUY$55	38.40% Upside
Filippo FalorniCiti	PG Procter & Gamble	BUY$200	20.94% Upside

Daily Sell Ratings

Analyst & Firm	Company	Rating & Price Target	Upside / Downside
Devin McDermottMorgan Stanley	RRC Range Resources	SELL$38	-8.32% Downside
Mehdi HosseiniSusquehanna	STX Seagate Tech	SELL$68	-37.75% Downside
Devin McDermottMorgan Stanley	MUR Murphy Oil	SELL$37	18.59% Upside

Full List of Stock Ratings

(Jan 22, 2025)

Analyst Performance

Any

Analyst Rating

Any

Upside / Downside

Any

Action

Any

Market Cap

Any

Analyst & Firm	Company	Rating & Price Target	Upside / Downside	Average Return	Action	Date	Article
Andrew Mok CFABarclays	HUM Humana	HOLD $253→$255	―	-9.30%	Reiterated	2025-01-22	Humana price target raised to $255 from $253 at Barclays
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	BUY $54	―	5.90%	Upgraded	2025-01-22
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	HOLD $22→$15	―	5.10%	Downgraded	2025-01-22
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	BUY $36→$39	―	13.90%	Reiterated	2025-01-22
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	BUY $21→$28	―	13.90%	Reiterated	2025-01-22
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	BUY $145→$125	―	1.70%	Reiterated	2025-01-22
Michael FunkBank of America Securities	TWLO Twilio	SELL $65	―	-6.40%	Reiterated	2025-01-22	Bearish Outlook on Twilio: Sell Rating Due to Overvaluation and Competitive Pressures
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	BUY $57	―	9.70%	Assigned	2025-01-22
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	BUY $117	―	7.00%	Assigned	2025-01-22
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	BUY $800→$1,150	―	2.20%	Reiterated	2025-01-22
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	BUY $315→$440	―	54.00%	Reiterated	2025-01-22
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	HOLD $21→$23	―	54.00%	Reiterated	2025-01-22
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	BUY $20	―	12.30%	Upgraded	2025-01-22
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	SELL $18	―	8.50%	Reiterated	2025-01-22
Gil BlumNeedham	ABSI AbSci	BUY $9	―	-8.70%	Initiated	2025-01-22	Absci initiated with a Buy at Needham
Max SmockWilliam Blair Not Ranked	CRL Charles River Labs	HOLD	―	―	Downgraded	2025-01-22	Charles River downgraded to Market Perform from Outperform at William Blair
Michael MatsonNeedham	ATRC Atricure	BUY $40→$51	―	-4.00%	Reiterated	2025-01-22	Analysts Conflicted on These Healthcare Names: Atricure (NASDAQ: ATRC) and Hims & Hers Health (NYSE: HIMS)
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	HOLD $23→$22	―	11.80%	Reiterated	2025-01-22
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	BUY $232	―	18.80%	Assigned	2025-01-22
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	BUY $141→$147	―	17.10%	Initiated	2025-01-22
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	BUY $21	―	21.60%	Assigned	2025-01-22
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	BUY $28	―	13.70%	Reiterated	2025-01-22
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	HOLD $86	―	16.30%	Reiterated	2025-01-22
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	HOLD $70	―	13.70%	Assigned	2025-01-22
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	BUY $11→$16	―	62.10%	Reiterated	2025-01-22
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	BUY $115→$160	―	20.70%	Reiterated	2025-01-22
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	BUY $125→$135	―	20.70%	Reiterated	2025-01-22
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	HOLD $125	―	20.00%	Assigned	2025-01-22
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	HOLD $95→$105	―	34.40%	Reiterated	2025-01-22
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	HOLD $76	―	33.10%	Assigned	2025-01-22
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	BUY $70	―	14.40%	Assigned	2025-01-22
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	BUY $54→$70	―	20.70%	Reiterated	2025-01-22
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	HOLD $58	―	14.40%	Assigned	2025-01-22
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	BUY $57	―	19.30%	Assigned	2025-01-22
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	HOLD $51	―	21.60%	Assigned	2025-01-22
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	BUY $45	―	20.30%	Initiated	2025-01-22
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	BUY $43	―	14.40%	Assigned	2025-01-22
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	HOLD $42	―	20.00%	Reiterated	2025-01-22
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	HOLD $36	―	11.20%	Assigned	2025-01-22
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	HOLD $36	―	16.30%	Assigned	2025-01-22
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	HOLD $32	―	16.30%	Assigned	2025-01-22
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	HOLD $23	―	13.70%	Assigned	2025-01-22
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	HOLD $135	―	14.40%	Assigned	2025-01-22
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	BUY $93	―	10.70%	Assigned	2025-01-22
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	HOLD $183	―	15.10%	Assigned	2025-01-22
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	BUY $17	―	68.70%	Assigned	2025-01-22
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	HOLD $145	―	13.70%	Assigned	2025-01-22
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	HOLD $110	―	19.30%	Assigned	2025-01-22
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	HOLD $37	―	14.40%	Assigned	2025-01-22
xxxxxxxxxxxxxxxxxx	xxxxxxxxxxxxxxxxxxxxxxxxxxx	HOLD $27	―	20.00%	Assigned	2025-01-22

Rows:

Ready for the Full Picture?Your current plan limits your access to top-tier analyst ratings. Subscribe to Premium now and unlock the full range of ratings from the highest-ranked analysts on Wall Street. Don't let partial views limit your market research potential - upgrade today!

Upgrade Now Plans & Pricing